Recurrent or metastatic head and neck cancer gives a median survival of ten to thirteen months on first-line therapy.1

About one in six HPV-negative tumors recurs locally within three years even after complete surgery and postoperative chemoradiation.2

The head and neck cancer patients with the worst prognosis receive the same protocol as those with the best. Stratifying by biology is long overdue.

Please note: Corvexa Tx operates in a stealth capacity.

We read what comes in and answer where we can. Nothing you send is used for anything but a reply. Privacy policy.